What's new in preventing and treating osteoporosis?

References

• DeCherney A. Bone-sparing properties of oral contraceptives. Am J Obstet Gynecol 1996; 174(1 Pt 1):15–20
   Google Scholar
• Barrett-Connor E, Chang JC, Edelstein SL. Coffee-associated osteoporosis offset by daily milk consumption: the Rancho Bernardo Study. JAMA 1994; 271 (4):280–3
   Web of Science ®Google Scholar
• Lindsay R, Hart DM, Aitken JM, et al. Long-term prevention of postmenopausal osteoporosis by oestrogen: evidence for an increased bone mass after delayed onset of oestrogen treatment. Lancet 1976; 1(7968):1038–41
   PubMed Web of Science ®Google Scholar
• Christiansen C, Christensen MS, Transbol I. Bone mass in postmenopausal women after withdrawal of oestrogen/gestagen replacement therapy. Lancet 1981; 1 (8218):459–61
   PubMed Web of Science ®Google Scholar
• Schneider DL, Barrett-Connor EL, Morton DJ. Timing of postmenopausal estrogen for optimal bone mineral density: the Rancho Bernardo Study. JAMA 1997; 277(7):543–7
   Web of Science ®Google Scholar
• Weiss NS, Ure CL, Ballard JH, et al. Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen. N Engl J Med 1980; 303(21):1195–8
   PubMed Web of Science ®Google Scholar
• Jensen JS, Tondevold E. Mortality after hip fractures. Acta Orthop Scand 1979; 50(2):161–7
   PubMed Web of Science ®Google Scholar
• Lindsay R, Tohme JF. Estrogen treatment of patients with established postmenopausal osteoporosis. Obstet Gynecol 1990; 76(2):290–5
   Google Scholar
• Naessen T, Persson I, Adami HO, et al. Hormone replacement therapy and the risk for first hip fracture: a prospective, population-based cohort study. Ann Intern Med 1990; 113(2):95–103
   PubMed Web of Science ®Google Scholar
• Marcus R, Greendale G, Blunt BA, et al. Correlates of bone mineral density in the Postmenopausal Estrogen/Progestin Interventions trial. J Bone Miner Res 1994; 9(9):1467–76
   Google Scholar
• Lindsay R. Hormone replacement therapy for prevention and treatment of osteoporosis. Am J Med 1993; 95(5A):37–9S
   Google Scholar
• Ettinger B, Genant HK, Cann CE. Postmenopausal bone loss is prevented by treatment with low-dosage estrogen with calcium. Ann Intern Med 1987; 106(1):40–5
   PubMed Web of Science ®Google Scholar
• Abdalla HI, Hart DM, Lindsay R, et al. Prevention of bone mineral loss in postmenopausal women by norethisterone. Obstet Gynecol 1985; 66(6):789–92
   PubMed Web of Science ®Google Scholar
• Genant HK, Lucas J, Weiss S, et al, for the Estratab/Osteoporosis Study Group. Low-dose esterified estrogen therapy: effects on bone, plasma estradiol concentrations, endometrium, and lipid levels. Arch Intern Med 1997; 157(22):2609–15
   Google Scholar
• Watson NR, Studd JW, Garnett T, et al. Bone loss after hysterectomy with ovarian conservation. Obstet Gynecol 1995; 86(1): 72–7
   Google Scholar
• Emans SJ, Grace E, Hoffer FA, et al. Estrogen deficiency in adolescents and young adults: impact on bone mineral content and effects of estrogen replacement therapy. Obstet Gynecol 1990; 76(4);585–92
   Google Scholar
• Andrews WC. The transitional years and beyond. Obstet Gynecol 1995; 85(1):1–5
   Google Scholar
• Persson I, Adami HO, Bergkvist L, et al. Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study. BMJ 1989; 298(6667): 147–51
   PubMed Web of Science ®Google Scholar
• Willis DB, Calle EE, Miracle-McMahill HL, et al. Estrogen replacement therapy and risk of fatal breast cancer in a prospective cohort of postmenopausal women in the United States. Cancer Causes Control 1996; 7(4):449–57
   PubMed Web of Science ®Google Scholar
• Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995; 332(24):1589–93
   PubMed Web of Science ®Google Scholar
• Daly E, Vessey MP, Hawkins MM, et al. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996; 348(9033):977–80
   PubMed Web of Science ®Google Scholar
• Jick H, Derby LE, Myers MW, et al. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 1996; 348(9033):981–3
   Google Scholar
• Grodstein F, Stampfer MJ, Goldhaber SZ, et al. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet 1996; 348(9033):983–7
   PubMedGoogle Scholar
• Thomas MK, Lloyd-Jones DM, Thadhani RI, et al. Hypovitaminosis D in medical inpatients. N Engl J Med 1998; 338(12):777–83
   PubMed Web of Science ®Google Scholar
• Hosking D, Chilvers CE, Christiansen C, et al, for the Early Postmenopausal Intervention Cohort Study Group. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. N Engl J Med 1998; 338(8):485–92
   PubMed Web of Science ®Google Scholar
• Liberman UA, Weiss SR, Broil J, et al, for the Alendronate Phase III Osteoporosis Treatment Study Group. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995; 333(22):1437–43
   PubMed Web of Science ®Google Scholar
• de Groen PC, Lubbe DF, Hirsch LJ, et al. Esophagitis associated with the use of alendronate. N Engl J Med 1996; 335(14):1016–21
   PubMed Web of Science ®Google Scholar
• Storm T, Thamsborg G, Steiniche T, et al. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 1990; 322(18):1265–71
   PubMed Web of Science ®Google Scholar
• Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997; 337(23):1641–7
   PubMed Web of Science ®Google Scholar
• Clarkson TB, Anthony MS, Jerome CP. Lack of effect of raloxifene on coronary artery atherosclerosis of postmenopausal monkeys. J Clin Endocrinol Metab 1998; 83(3):721–6
   Google Scholar
• Overgaard K, Lindsay R, Christiansen C. Patient responsiveness to calcitonin salmon nasal spray: a subanalysis of a 2-year study. Clin Ther 1995; 17(4):680–5
   Google Scholar